key: cord-0721635-1zkmo4n9
authors: Moores, Lisa K.; Tritschler, Tobias; Brosnahan, Shari; Carrier, Marc; Collen, Jacob F.; Doerschug, Kevin; Holley, Aaron B.; Iaccarino, Jonathan; Jimenez, David; LeGal, Gregoire; Rali, Parth; Wells, Philip
title: Thromboprophylaxis in Patients with COVID-19. A Brief Update to the CHEST Guideline and Expert Panel Report
date: 2022-02-12
journal: Chest
DOI: 10.1016/j.chest.2022.02.006
sha: 0c537f9515cbcb2cc80d83cd270789e89d931c70
doc_id: 721635
cord_uid: 1zkmo4n9

Background Patients hospitalized with COVID-19 often exhibit markers of a hypercoagulable state and have an increased incidence of venous thromboembolism (VTE). In response, CHEST issued rapid clinical guidance regarding prevention of VTE. Over the past 18 months the quality of the evidence has improved. We thus sought to incorporate this evidence and update our recommendations as necessary. Methods This update focuses on the optimal approach to thromboprophylaxis in hospitalized patients. The original questions were used to guide the search, using MEDLINE via PubMed. Eight randomized controlled trials and one observational study were included. Meta-analysis, using a random effects model, was performed. The panel created summaries using the GRADE Evidence-to-Decision framework. Updated guidance statements were drafted, and a modified Delphi approach was used to obtain consensus. Results We provide separate guidance statements for VTE prevention for acutely (moderately) ill hospitalized patients and critically ill patients in the ICU. However, we divided each original question and resulting recommendation into two questions: standard prophylaxis vs. therapeutic (or escalated dose) prophylaxis and standard prophylaxis vs. intermediate dose prophylaxis. This led to a change in one recommendation, and an upgrading of three additional recommendations based upon higher quality evidence. Conclusions Advances in care for patients with COVID-19 have improved overall outcomes. Despite this, rates of VTE in these patients remain elevated. Critically ill patients should receive standard thromboprophylaxis for VTE and moderately ill patients with a low bleeding risk might benefit from therapeutic heparin. We see no role for intermediate dose thromboprophylaxis in either setting.

Within the first few months of the COVID-19 global pandemic, it was recognized that patients hospitalized with SARS-CoV-2 often exhibited markers of a hypercoagulable state and had an increased incidence of venous thromboembolism (VTE). Reports documented significantly elevated D-dimer levels that were associated with increased morbidity and mortality. 1, 2 This led many professional societies, including CHEST 3 , to develop rapid guidance documents regarding the optimal strategy for prophylaxis of VTE in these patients. [4] [5] [6] [7] [8] [9] [10] Initially, evidence was extremely limited and consisted of fewer than 30 retrospective cohort studies of varying size that reported on patients from varied geographic regions and clinical settings. There was no universal approach to screening or diagnosis. Perhaps most importantly, the thromboprophylaxis regimens varied across studies and were sometimes not reported at all. Based upon the limited, low-quality evidence suggesting patients with COVID-19 pneumonia had a higher risk of thrombosis than similarly ill patients without COVID-19, societal guidelines were uniform in their recommendation that all hospitalized patients with COVID-19 pneumonia receive pharmacologic thromboprophylaxis in the absence of a contraindication. Recommendations regarding the optimal dosing, however, varied. Some, including CHEST, recommended standard dose prophylaxis for all patients, while a few suggested that intermediate or therapeutic dosing could be considered, especially in patients admitted to the intensive care unit. See Table 1 for a summary of these early recommendations.

Since then, our understanding of the underlying pathophysiologic mechanisms of this prothrombotic state has advanced. While it is beyond the scope of this manuscript to describe these mechanisms in detail, it should be noted that there are two distinct but related processes: a hypercoagulable state that leads to large vessel macro thrombosis and a primary endotheliopathy that results in extensive in-situ, immunothrombosis. A more detailed review of these mechanisms has recently been published. 11 Over the past 15 months, we have also seen the emergence of randomized controlled trials (RCTs) focusing on the optimal dosing for thromboprophylaxis in both moderately ill hospitalized (non-ICU) and critically ill (ICU) patients. Here we provide updated guidance focused on prevention of thrombosis in hospitalized patients. We are not updating any prior guidance related to pre-or post-hospital prophylaxis, diagnosis, or treatment.

The panel followed standard CHEST process for the development of rapid guidance statements, as detailed in the first version of this guideline. 3 Conflict of interest declarations were reviewed for all panelists by the Professional Standards Committee. No panelist required any management for the topic areas being updated. The panel was aware of recently published or studies expected to be published soon regarding optimal thromboprophylaxis and thus chose to limit this update to guidance statements in this topic area. The original Population, Intervention, Comparator, Outcome (PICO) questions were used to guide the search, using MEDLINE via PubMed. Screening and full text selection were performed in duplicate by pairs of panel members. Additional studies were identified by panel members as they were published. Included studies [12] [13] [14] [15] [16] [17] [18] [19] [20] are outlined in Table 2 .

Risk of bias was assessed by the methodologist using Version 2 of the Cochrane risk-of bias tool for randomized trials (RoB 2). 21 Data abstraction was done in duplicate. Any discrepancies were resolved through consensus. Primary outcomes included VTE (pulmonary embolism [PE] and deep vein thrombosis [DVT]), fatal PE, major bleeding, fatal bleeding, mortality, and organ support-free days (OSFDs). As our original guideline focused on VTE, we did not include arterial thrombosis as an outcome. A meta-analysis, using a random effects model, was performed.

The panel then created summaries using the GRADE Evidence-to-Decision framework. 22 These summaries were discussed by the entire group, and updated guidance statements were suggested and voted upon using a modified Delphi approach. This approach utilized several rounds of anonymous voting, with survey results and comments presented to the panel after each round until consensus was achieved. Per CHEST policy, consensus was defined as at least 80% agreement for each recommendation with at least 75% voting participation rate from the panel. Recommendation 1 was controversial and required four rounds of voting (see context comments below. Recommendation 2 reached consensus in three rounds of voting. Recommendations 3 and 4 each reached consensus after two rounds of voting.

As in the first version of the guideline, we chose to provide separate guidance statements for VTE prevention for acutely ill hospitalized patients (also described as moderately ill, or non-ICU patients) and critically ill patients either hospitalized in the ICU or receiving ICU level care. However, we divided each original PICO question and resulting recommendation into two questions: standard prophylaxis vs. therapeutic (or escalated dose) prophylaxis and standard prophylaxis vs. intermediate dose prophylaxis.

There were four studies reporting on 3475 patients addressing this question, the largest being the multiplatform ATTACC, ACTIV-4a, and REMAP-CAP study 12 that enrolled 2244 patients. Additional studies included the ACTION 16 , RAPID 19 , and HEP-COVID 20 trials. For both the multiplatform 12 and HEP-COVID 20 trials, we were only able to include PE as DVT rates were not mutually exclusive from PE. There was a reduction in any VTE in the therapeutic anticoagulation group (risk ratio [RR] 0.48 [95% CI 0.30-0.78]), at the expense of increased major bleeding (RR 1.79 [95% CI 1.01-3.16]) (Figure 1a/1b). No data regarding fatal PE could be extracted. Fatal bleeding was extremely rare and occurred in 0.3% (3/1180) of the therapeutic anticoagulation group compared to 0.1% (1/1047) in the thromboprophylaxis group in the multiplatform trial. The RAPID 19 trial reported no fatal bleeding in either group. There was no statistically significant difference in mortality between therapeutic and prophylactic anticoagulation (RR 0.75 [95% CI 0.41-1.37]) ( Figure 1c ). Therapeutic anticoagulation increased OSFDs compared to usual care with an OR of 1.27 (95% CI 1.03-1.58) in the multiplatform trial. 12 The RAPID 19 trial noted a statistically insignificant increased odds of OSFDs in the therapeutic group with an OR of 1.41 (95% CI 0.90-2.20) and the HEP-COVID 20 trial reported 7/84 (8.3%) in therapeutic group required mechanical ventilation compared to 13/86 (15.1%) in the thromboprophylaxis group. After considerable discussion and four rounds of voting, the panel reached consensus on the following recommendation.

Remarks: Providers should carefully weigh the risks of thrombosis and bleeding in making this decision. Patients with an significantly elevated D-dimer level (studies have previously defined this as 2-4x the upper limit of normal), those with prior VTE, or other comorbidities known to be associated with VTE may be at increased risk of thrombosis. Patients with high risk of bleeding include, but are not limited to, those with known bleeding within the last 30 days requiring emergency room presentation or hospitalization, known history of an inherited or acquired bleeding disorder, active dual antiplatelet therapy, recent ischemic stroke, intracranial malignancy, history of bleeding diatheses (e.g., hemophilia), history of gastrointestinal bleeding within previous 3 months, thrombolysis within the previous 7 days, presence of an epidural or spinal catheter; recent major surgery <14 days, or uncontrolled hypertension (sBP >200 mmHg, dBP >120 mmHg).

The panel struggled to come to consensus on this recommendation. From a pure VTE perspective, these trials are consistent with historical trials---therapeutic heparin, either intravenous UFH or full dose LMWH, reduces VTE at the cost of increased bleeding, without any benefit in overall mortality. The reporting of decreased OSFDs in the multiplatform trial 12 deserves notice but is not a typical outcome used in VTE studies. That said, in balance, the benefits of therapeutic vs. prophylactic dosing appears to favor the former. Several nuanced issues beyond this were discussed. The ACTION 16 trial, which was the only to use therapeutic doses of rivaroxaban as opposed to heparin, showed no overall benefit. To explain this, we might invoke that there are additional pleiotropic and/or anti-inflammatory effects of heparin that are beneficial beyond the benefits of thromboprophylaxis. While plausible, studies in similarly ill patients without COVID-19 have been inconclusive. The panel also noted the inconsistency in effect between acutely (moderately) ill hospitalized patients and critically ill patients, with the OSFD benefit only being seen in the former. This invokes a hypothesis regarding timing of the initiation. Perhaps early administration of therapeutic heparin does indeed affect the underlying pathophysiologic mechanisms in a way that reduces macro and microthrombosis, but once patients develop more severe end-organ damage, the harmful effects outweigh any benefit. This is also plausible, but not fully studied. Another concern raised was the likelihood of ascertainment bias (patients in the therapeutic arm of an open label trial may be less likely to undergo diagnostic testing for VTE). Finally, the panel raised concern that the extremely low rate of bleeding in these trials does not match real world rates, perhaps because patients with high risk of bleeding were excluded, and thus assessment of bleeding risk is paramount in decision making. Panel members also pointed out the heterogeneous populations included in the trials and the known changes in standard management over time. Given all of this, the panel voted to make a conditional recommendation in favor of therapeutic anticoagulation, while noting in the remarks that the decision should be based upon the risk of thrombosis (those with higher D-Dimer levels or other risks for VTE may be at higher risk) and the risk of bleeding (see Table 3 for a more extensive list of factors associated with an increased risk of bleeding). Although consensus was reached, one panel member strongly disagreed with this recommendation.

There were no randomized trials addressing this question. The only study to inform this question was an observational cohort that reported on rates of VTE stratified by thromboprophylaxis received. 14 The rate of VTE in the intermediate dosing group was 7/33 (21%) and in the prophylactic dose group, 20/67 (30%). Bleeding estimates were not reported. Given our original recommendation against intermediate dosing in these patients, the evidence already presented above for consideration of therapeutic dosing in this cohort, and the lack of any evidence suggesting clear benefit of this approach, the panel voted to endorse the prior recommendation, with consensus reached after one round of voting.

Given the lack of RCTs to address this question, there was unanimous agreement regarding this recommendation. Panel members also noted that 'intermediate dose anticoagulation' leaves too much room for error and confusion in clinical practice.

For this analysis, we chose to include all studies that compared standard thromboprophylaxis dosing to "escalated" dosing (intermediate or therapeutic). This was done because the panel recognized that common practice in many ICU settings includes varying escalated dosing protocols. There were five studies to inform this question, which included a total of 1947 patients. Again, the largest was the multiplatform ATTACC, ACTIV-4a, and REMAP-CAP 13 trial which accounted for 1089 patients. Additional studies included the HESACOVID 15 , INSPIRATION 18 , HEP-COVID 20 , and Perepu 17 studies. It should be noted that the multiplatform trial and the HEP-COVID trial reflect PE data only. There were additional patients with DVT in each group, but we could not determine if these patients overlapped those with PE, thus they were excluded from analysis. Perepu 17 Six trials were included in the mortality analysis. In addition to the trials mentioned above, the ACTION 16 trial also included a small number of critically ill patients (n=39) that were incorporated in the analysis. There was no significant difference in mortality between the two groups (RR 1.03 [95%CI 0.91-1.15]) (Figure 2c ).

There was no disagreement about the direction of the recommendation. The data supporting thromboprophylaxis for the critically ill is quite robust. Other than the effect on PE seen in the multiplatform trial, there was insufficient evidence to suggest deviation from standard thromboprophylaxis. When all outcomes in the multiplatform trial, and not just PE, are factored in, the case against therapeutic anticoagulation is quite strong. Further, although the risk of VTE is likely lower on therapeutic anticoagulation (absolute risk reduction approximately 5%), the risk of major bleeding is higher (absolute risk increase approximately 1-2%), and there is no effect on mortality. Considering the risk of ascertainment bias for VTE in these open-label trials, the incomplete reporting of VTE events (no DVTs reported) and the high probability of inferiority of therapeutic anticoagulation compared to usual thromboprophylaxis for OSFDs in the multiplatform trial, the data thus far support continued use of existing guidelines.

For this question, we chose to focus on studies primarily designed specifically to evaluate intermediate dose thromboprophylaxis, as opposed to a combination of escalated doses. There were two studies to inform this question, the INSPIRATION 18 (Figure 3) . No data was reported regarding fatal PE. The INSPIRATION 18 trial reported that there was no difference between the two groups in ventilator-free days.

There was no disagreement in the direction of the recommendation. The panel noted that the INSPIRATION 18 trial, the largest, did not show a benefit in VTE reduction and yet there was a potential increase in bleeding risk (statistically not significant). Therefore, the panel considered upgrading the recommendation from conditional to strong. Some felt this was perhaps premature given some methodological issues of the study. Ultimately the panel chose to maintain the conditional recommendation in favor of standard thromboprophylaxis in this cohort.

This manuscript serves as a brief update to the original guidance statement. Although we have better quality evidence, many questions remain. Despite this, our panel felt that it was important to share our thoughts regarding the new evidence, especially as one recommendation differs in direction from the original publication, and the others have more evidence to support them. The decision to change the recommendation was not an easy one. While the new trials are higher quality evidence, the interpretation of the results is not without controversy. Progression of respiratory failure due to COVID-19 is a different endpoint than preventing VTE. In the end, we felt that it was an important endpoint. Some may question our decision not to include arterial thrombotic events as a primary outcome. These are clearly important to patients and clinicians. Our original publication, however, was focused on VTE and this was designed as an update to that publication. In addition, a recent meta-analysis that did include these events would not likely have changed our recommendations. 23 Questions remain and should guide further research. Does the timing of heparin administration affect the ultimate outcome? Should patients admitted to the ICU during their admission continue therapeutic heparin? Does heparin indeed have anti-inflammatory, antiviral, or other pleiotropic effects in COVID-19? Which mechanisms of the prothrombotic state are prominent, and does this influence the optimal approach? Are current standard therapies changing the baseline risk of VTE? Should the approach to vaccinated patients be any different than unvaccinated patients?

We have learned quite a bit regarding thrombosis in patients with COVID-19 pneumonia. Although advances in care have improved overall outcomes, current evidence supports that the rates of VTE are higher in these patients, at least in the ICU. 24, 25 At this time, we believe critically ill patients should still receive standard thromboprophylaxis for VTE and moderately ill patients with a low bleeding risk might benefit from therapeutic heparin. We see no role for intermediate dose thromboprophylaxis in either setting. The World Health Organization plans to perform a meta-analysis that includes several small trials along with the studies included here, and their findings may inform practice (PROSPERO registration ID is CRD42020213461). In addition, results from recently published trials examining the effect of pre-and post-hospital prophylaxis may lead to additional guideline updates. J o u r n a l P r e -p r o o f 

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Characteristics of emergency patients with markedly elevated D-dimer levels

Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease

NICE COVID-19 management

COVID-19 clinical management: living guidance. World Health Organization

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine

COVID-19) Treatment Guideines

Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

Pulmonary Thrombosis and Thromboembolism in COVID-19

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

COVID-19 Infection in Critically Ill Patients Carries a High Risk of Venous Thrombo-embolism

Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial

Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial

RoB 2: a revised tool for assessing risk of bias in randomised trials

GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines

Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials

Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Metaanalysis

Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: A systematic review with meta-analysis